Sarah Eliuth Ochoa Hugo | Nanomedicine | Young Scientist Award

Published on by Top Pharmaceutical

Dr. Sarah Eliuth Ochoa Hugo | Nanomedicine | Young Scientist Award

Dr. Sarah Eliuth Ochoa Hugo at Center of Research and Assistance in Technology and Design of the State of Jalisco| Mexico

Dr. Sarah Eliuth Ochoa Hugo is a dedicated pharmaceutical chemist, biotechnologist, and researcher specializing in medical and pharmaceutical innovation. Currently pursuing her Ph.D. in Biotechnological Innovation Applied to Health at CIATEJ, she integrates her expertise in biotechnology, nanotechnology, and pharmacology to address critical challenges in cancer, Alzheimer’s disease, and medical device safety. As a lecturer at Universidad del Valle de México, she mentors future health professionals, guiding them in scientific research and publication. Alongside academia, she engages in entrepreneurial initiatives that merge scientific innovation with social impact, demonstrating her commitment to advancing healthcare through research, education, and applied technology.

Publication Profile 

Orcid

Education 

Dr. Sarah Eliuth Ochoa Hugo is currently a Ph.D. candidate in Biotechnological Innovation Applied to Health at CIATEJ, focusing on advanced biomedical solutions. She previously earned her Master of Science in Biotechnological Innovation Applied to Medical and Pharmaceutical Sciences at CIATEJ, where her thesis explored exosomal cargo in Alzheimer’s pathogenesis. Her academic foundation was built at Universidad del Valle de México, where she completed a Bachelor of Science in Pharmaceutical Chemistry and Biotechnology. There, she validated a 3D glioblastoma multiforme culture model. Complementing her degrees, she has completed certifications in pharmaceutical regulation, medical English, cancer biology, pharmacology, and advanced English proficiency.

Experience 

Dr. Sarah Eliuth Ochoa Hugo serves as an undergraduate lecturer in Health Sciences at Universidad del Valle de México, where she promotes research-oriented learning and student publications. She is co-founder of Quality Approvers, a startup advancing process optimization using Lean and Six Sigma methodologies. Previously, she worked as a Pharmaceutical Chemist and Assistant Sanitary Responsible at San Javier Hospital, ensuring pharmaceutical compliance and safety. During the pandemic, she launched Paihuenk, a social entrepreneurship project producing artisanal cosmetics to support local communities. With extensive academic and industry experience, she bridges biomedical research, pharmaceutical practice, and innovation-driven entrepreneurship in health and biotechnology.

Awards and Honors 

Dr. Sarah Eliuth Ochoa Hugo achievements are reflected through her strong academic and research portfolio, including international presentations at the Society for Neuroscience meetings in San Diego and publications in prominent journals. Her certification by COFEPRIS in pharmaceutical dispensing underscores her compliance with industry standards, while academic training from King’s College London, Monash University, and Johns Hopkins has expanded her global expertise. At Universidad del Valle de México, she has been recognized for her excellence in teaching, demonstrated. Her contributions to translational research and community-focused entrepreneurship highlight her growing academic influence.

Research Focus 

Dr. Sarah Eliuth Ochoa Hugo research focuses on cancer therapy, Alzheimer’s disease, and medical device vigilance through biotechnological innovation. She has explored 3D glioblastoma culture models, evaluated phenolic compounds for anticancer activity, and investigated exosomal cargo in Alzheimer’s disease. Her recent work integrates nanotechnology, particularly gold nanostructures, for photothermal therapies in colon cancer. Additionally, she contributes to medical device monitoring and pharmaceutical safety through technovigilance research. Her multidisciplinary approach combines molecular biology, pharmacology, and nanomedicine, aiming to design innovative therapies with clinical applications. By integrating biotechnology with applied health sciences, her work advances precision medicine, preventive care, and translational biomedical innovation.

Publication Top Notes

Xiao Sheng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Xiao Sheng | Drug Discovery and Development | Best Researcher Award

lecturer at Naval Medical University School of Pharmacy | China

Dr. Xiao Sheng is a distinguished researcher in biochemistry and molecular biology at the Navy Medical University, China. His work bridges traditional Chinese medicine, molecular signaling, and intestinal health, with a focus on aging and regenerative biology. As a principal investigator of multiple funded projects, he has made significant contributions to understanding mechanisms of intestinal stem cell regulation, tumor progression, and herbal medicine efficacy. His publications in high-impact journals highlight pioneering findings in antioxidant pathways, stem cell biology, and gut regeneration. Dr. Xiao is actively engaged in international collaborations, scientific societies, and editorial responsibilities in biomedical research.

Publication Profile 

Orcid

Education 

Dr. Xiao Sheng completed his academic training in biochemistry and molecular biology, developing a strong foundation in cellular and molecular research. At the Navy Medical University, he pursued advanced education integrating biomedical sciences with translational research approaches. His education emphasized experimental medicine, molecular signaling pathways, and the application of traditional Chinese medicine concepts within modern biological frameworks. This interdisciplinary training enabled him to explore the interaction between cellular metabolism, intestinal regeneration, and aging biology. His academic preparation laid the groundwork for his later success as a principal investigator and contributed to his leadership in national and international scientific initiatives.

Experience 

Dr. Xiao Sheng  has extensive experience leading research in biochemistry, molecular biology, and translational medicine. As principal investigator, he heads projects supported by Anhui Provincial Engineering Technology Research Center and the Second Military Medical University, focusing on intestinal injury repair, tumor biology, and herbal medicine. His work extends to national research initiatives such as the National Key R&D Program and the National Natural Science Foundation of China, where he has contributed as a key participant. He has authored numerous peer-reviewed publications, serves on editorial boards, and holds active memberships in professional committees, advancing biomedical research and international scientific collaboration.

Awards and Honors 

Dr. Xiao Sheng has received multiple recognitions for his scientific contributions. He earned the Outstanding Poster Award at the International and Chinese Drosophila Biology Congress, demonstrating the novelty of his research in model organisms. His innovative approaches to Chinese medicine research were honored with the Third Prize in the Traditional Chinese Medicine Group at the National Undergraduate Forum on Innovative Research in Basic Medicine and Experimental Design. Recently, he was named a “Shizhen Scholar,” reflecting his leadership and excellence in integrating traditional medicine with modern molecular biology. These awards underscore his contributions to translational and interdisciplinary biomedical research.

Research Focus 

Dr. Xiao’s  Sheng  research centers on molecular mechanisms regulating intestinal stem cell biology, aging, and regenerative medicine. He explores how herbal medicine compounds influence cellular pathways, particularly the Keap1–Nrf2 signaling axis, to mitigate intestinal injury and aging-related disorders. His studies extend to tumor biology, focusing on how nuclear lamina proteins drive cancer development through cell competition. Additionally, he investigates molecular regulators of gut regeneration, including transcription factors and RNA modifications. His interdisciplinary approach combines traditional Chinese medicine with modern molecular biology, advancing novel therapeutic strategies. His work holds promise for improving treatments for age-related diseases and metabolic disorders.

Publication Top Notes

Unlocking nature’s medicine cabinet through Drosophila–Driven exploration

Werner syndrome exonuclease promotes gut regeneration and causes age-associated gut hyperplasia in Drosophila

Phase separation of BuGZ regulates gut regeneration and aging through interaction with m6A regulators

Antioxidant Effects of Caffeic Acid Lead to Protection of Drosophila Intestinal Stem Cell Aging

Aging-related upregulation of the homeobox gene caudal represses intestinal stem cell differentiation in Drosophila

Denise Faustman | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Denise Faustman | Immunotherapy | Best Researcher Award

Associate Professor of Medicine at Harvard Medical School  | United States

Dr. Denise Faustman is a physician-scientist recognized for her pioneering work in immunology, autoimmunity, and type 1 diabetes research. She serves as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Her career bridges clinical medicine, molecular biology, and translational research, with a focus on advancing novel therapies for autoimmune diseases. Dr. Faustman has significantly contributed to understanding immune tolerance, vaccine-based interventions, and the role of BCG vaccination in autoimmune modulation. She is widely respected for her leadership, scientific advisory roles, and commitment to women’s health and immunological innovation.

Publication Profile 

Scopus

Education

Dr. Denise Faustman earned a B.S. in Zoology and Chemistry from the University of Michigan, followed by an M.D. and Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine in St. Louis. She completed her postdoctoral training in transplantation immunology at Washington University before pursuing clinical training in internal medicine and endocrinology at Massachusetts General Hospital and Harvard Medical School. Her combined training in medicine, molecular biology, and immunology has uniquely positioned her to integrate clinical insights with advanced laboratory science, fueling her translational research on autoimmunity, immunotherapy, and novel strategies for the treatment of chronic diseases.

Experience 

Dr. Denise Faustman has built a distinguished career at Harvard Medical School and Massachusetts General Hospital, where she directs the Immunobiology Laboratory. Her academic roles span from Instructor to Associate Professor of Medicine, combined with leadership in clinical and translational immunology. She has served on numerous national and international scientific committees, including advisory roles at the FDA, NIH, NAS, and Institute of Medicine. As a physician-scientist, she bridges patient care with laboratory innovation, advancing novel treatments for autoimmune diseases. She has also provided scientific leadership for biotech companies, foundations, and research councils, shaping biomedical policy, discovery, and translational impact.

Awards and Honors 

Dr. Denise Faustman contributions have been recognized through prestigious appointments and leadership roles. She has served as Chair and Board Member of the Society for Women’s Health Research, Advisory Committee Member for the FDA, and Chair of national immunology and autoimmunity symposia. She has been elected to scientific advisory boards for biotechnology companies and foundations worldwide, including Sjögren’s Syndrome Foundation and Farallone Therapeutics. Her expertise has been sought by NASA, NIH, and the Department of Defense for defining priorities in immunology, vaccine safety, and women’s health. These roles reflect her influence, innovation, and leadership in advancing immunological and biomedical sciences.

Research Focus 

Dr. Denise Faustman research centers on autoimmunity, immune regulation, and translational immunotherapy. Her laboratory is internationally recognized for pioneering studies on immune tolerance and the use of BCG vaccine as a potential therapy for type 1 diabetes. She investigates mechanisms of T cell regulation, biomarkers for autoimmune progression, and pathways of immune modulation to translate discoveries into clinical applications. Her work bridges fundamental immunology with patient-centered research, aiming to develop safe, effective, and durable treatments for chronic autoimmune diseases. By integrating laboratory science, clinical trials, and translational medicine, Dr. Faustman is shaping innovative therapeutic strategies with global health impact.

Publication Top Notes

The spleen assumes a major role in blood glucose regulation in type 1 diabetes patients treated with BCG

Late in the US pandemic, multi-dose BCG vaccines protect against COVID-19 and infectious diseases

Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Association of BCG Vaccine Treatment with Death and Dementia in Patients with Non-Muscle-Invasive Bladder Cancer

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells

Letter to the Editor Regarding “The Non-Significant Benefit of BCG Vaccination for the Treatment of Iranian Patients with Type 1 Diabetes up to 48 Weeks: A Controversial Result”

The benefits of clustering in TNF receptor superfamily signaling

Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies

BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes

Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes

Maria Garrido | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Dr. Maria Garrido | Personalized Medicine | Women Researcher Award

Doctor at Hospital Universidtario 12 de octubre-Universidad Complutense de Madrid | Spain

Dr. Maria Garrido is a physician-scientist specializing in pathology and translational oncology with a focus on melanoma and cutaneous lymphomas. She earned her medical degree from the University of Granada and her PhD in Health Sciences and Biomedicine from Universidad Complutense de Madrid. With extensive international experience at the University of California San Francisco and Memorial Sloan Kettering, her research has contributed to landmark discoveries in oncogenes, fusion kinases, and tumor biomarkers. She currently works in dermatopathology and oncology research, collaborating with leading groups in Europe and internationally to advance personalized cancer diagnostics and therapeutic strategies.

Publication Profile 

Orcid

Education 

Dr. Maria Garrido obtained her medical degree in Medicine and Surgery from the University of Granada. She pursued her residency in Anatomical Pathology at Hospital Universitario 12 de Octubre, Madrid, and later completed a PhD in Health Sciences and Biomedicine at Universidad Complutense de Madrid. Complementing her medical and scientific training, she earned a Master’s in Clinical Management, Medical, and Healthcare Leadership from Universidad Tecnológica. Her academic formation integrates rigorous clinical foundations with molecular oncology research, allowing her to bridge patient care and translational science. She has continued to enhance her expertise through national and international academic fellowships.

Experience 

Dr. Maria Garrido has served as a resident and clinical specialist in pathology at major Spanish hospitals, including Hospital 12 de Octubre, Hospital General de Móstoles, and Clinic Hospital of Barcelona. Internationally, she was a fellowship researcher at UCSF and Memorial Sloan Kettering, contributing to melanoma genetics and translational oncology. She has collaborated on groundbreaking discoveries, including oncogenes in uveal melanoma and fusion kinases in Spitz tumors. Currently, she is part of the dermatopathology and oncology research group at Hospital Universitario 12 de Octubre, Madrid, where she advances studies on melanoma, lymphomas, molecular biomarkers, and diagnostic innovations in cutaneous oncology.

Awards and Honors 

Dr. Maria Garrido has received notable recognition for her research contributions. She was awarded a mobility fellowship by the Spanish Ministry of Science and Innovation for professional development in computational pathology at Queen’s University, Belfast. Her discoveries, including the GNA11 oncogene and fusion kinases in melanocytic tumors, have been published in high-impact journals such as the New England Journal of Medicine, Nature Communications, and Nature Genetics. Her contributions to the field of melanoma genetics have been cited worldwide, shaping the understanding of tumor biology. She continues to be honored through invitations to collaborate on international research initiatives and networks.

Research Focus 

Dr. Maria Garrido research focuses on the molecular pathology of melanoma and cutaneous lymphomas. She has made significant contributions to identifying oncogenes such as GNA11 and GNAQ, which account for most uveal melanomas, and discovering kinase fusion proteins in Spitz tumors. Her work also includes genetic studies on desmoplastic melanoma highlighting NFKBIE mutations. More recently, she has contributed to refining the classification of cutaneous lymphomas and identifying new biomarkers to guide diagnosis, prognosis, and therapeutic response. Her approach integrates pathology, molecular biology, and translational medicine to improve personalized treatment strategies and enhance patient outcomes in oncology and dermatopathology.

Publication Top Notes

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Acute sarcoidosis as a harbinger for pancreatic adenocarcinoma

TERT promoter mutation in sebaceous neoplasms

Orbital Solitary Fibrous Tumor: Four Case Reports—Clinical and Histopathological Features

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma

Hani Serag | Nanomedicine | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Hani Serag | Nanomedicine | Best Researcher Award

Director, Division of Global Partnerships at University of Texas Medical Branch (UTMB) | United States

Dr. Hani Serag is a physician and public health specialist with extensive experience in health systems research, global health, and addressing health disparities. Currently serving as Director of the Division of Global Partnerships and Assistant Professor at the Department of Population Health and Health Disparities, University of Texas Medical Branch (UTMB), he leads multiple programs on chronic disease prevention, HIV screening, and global health diplomacy. With a strong history of academic, research, and policy leadership, Dr. Serag has collaborated with international organizations, academic institutions, and civil society networks to strengthen healthcare equity, health policy, and global partnerships.

Publication Profile 

Google Scholar

Education 

Dr. Hani Serag earned his MD (M.B., B.Ch) from the Faculty of Medicine, Ain Shams University, Cairo, Egypt. He holds a Master of Public Health (MPH) degree from the School of Public Health, University of Western Cape, South Africa, focusing on health systems research, monitoring and evaluation, health promotion, and primary healthcare. He further enhanced his expertise with advanced training in epidemiology, health care finance, biostatistics, and both quantitative and qualitative public health research methods through certificate programs at Erasmus University, Rotterdam, the Netherlands. His academic training integrates medicine, epidemiology, and public health with a global and systems-oriented perspective.

Experience 

Dr. Hani Serag has held key academic and leadership roles at UTMB, including Assistant Professor in Population Health and Endocrinology and Director of Global Partnerships. He has served as Principal Investigator for programs on chronic disease prevention, HIV screening, and international educational collaborations. His professional record includes consultancy and teaching engagements with the Pan American Health Organization (PAHO) and the World Health Organization (WHO). He previously served as Global Coordinator and Associate Global Coordinator for the People’s Health Movement, leading international initiatives on primary healthcare, social determinants of health, and global health governance. His work bridges academia, policy, and practice.

Awards and Honors 

Dr. Hani Serag contributions have been recognized through academic appointments across diverse disciplines including population health, internal medicine, pediatrics, and global health. His role as an Associate Member of the Graduate Faculty at UTMB highlights his mentorship of graduate students. He has been invited by WHO and PAHO for technical consultancies, curriculum development, and training programs, reflecting his international recognition in health systems and migration health research. Through his leadership in convening UTMB’s Annual Conference on Migration and Health and directing global health education initiatives, Dr. Serag has earned respect as a distinguished public health leader advancing health equity worldwide.

Research Focus 

Dr. Hani Serag research focuses on advancing health system responsiveness, reducing disparities, and integrating preventive care into clinical settings. His work emphasizes chronic disease prevention, HIV screening, and global health governance. He has designed and implemented multi-stakeholder programs that address the social determinants of health and promote patient-centered models of care. His scholarly contributions include health policy research, health systems evaluation, and migration and health studies. He has actively developed curricula, technical reports, and peer-reviewed publications to build capacity in health equity and health policy. His ongoing research strengthens global partnerships and evidence-based strategies in population health.

Publication Top Notes

Covid-19 pandemic and the social determinants of health

Explaining covid-19 performance: what factors might predict national responses?

High‐protein vs. standard‐protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro‐HEART trial

Improving the collection of race, ethnicity, and language data to reduce healthcare disparities: a case study from an academic medical center

Cultural diversity impacts caregiving experiences: a comprehensive exploration of differences in caregiver burdens, needs, and outcomes

Racial and geographic variation in leg amputations among Texans

Relative social standing and suicide ideation among Kenyan males: the interpersonal theory of suicide in context

Racial disparities in type of heart failure and hospitalization

Social determinants of health in countries in conflict and crises: the eastern Mediterranean perspective

Subjective social standing and conflict tactics among young Kenyan men

Illustrating the impact of commercial determinants of health on the global COVID-19 pandemic: Thematic analysis of 16 country case studies

Enabling structural resilience of street-involved children and youth in Kenya: reintegration outcomes and the Flourishing Community model

Understanding caregiver challenges: A comprehensive exploration of available resources to alleviate caregiving burdens

Coronavirus disease 2019, diabetes, and inflammation: A systemic review

Exploring the impact of ACA on rural‐urban disparity in oral health services among US noninstitutionalized adults

The association between mental well-being and school attendance among Palestinian adolescent refugees in UNRWA schools

Sapna B A | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Sapna B A | Cardiovascular Pharmacology | Best Researcher Award

Assitant Professor at KIT-Kalaignarkarunanidhi Institute of Technology | India

Dr. Sapna B A is an accomplished academic and researcher in the field of information and communication engineering, specializing in antenna design for biomedical, wearable, and wireless applications. With a strong foundation in electronics and communication, she has contributed significantly to developing advanced implantable and wearable antennas, focusing on safety and performance enhancements. Her career spans both academia and industry, with expertise ranging from teaching and mentoring to leading design projects in Dubai’s technology sector. Currently serving as Assistant Professor at Kalaignarkarunanidhi Institute of Technology, Coimbatore, she is recognized for impactful research, funded projects, and award-winning publications in reputed journals.

Publication Profile 

Orcid

Education 

Dr. Sapna B A earned her Ph.D. in Information and Communication Engineering from Anna University under the guidance of Dr. G. Srivatsun at PSG College of Technology, Coimbatore, with her thesis titled “High Performance Antennas for UWB Applications.” She completed her M.E. in Communication Systems from B S A Crescent Engineering College, Chennai, affiliated to Anna University, with a commendable. Her undergraduate studies were in Electronics and Communication Engineering at Jerusalem College of Engineering, University of Madras, where she obtained her B.E. degree. Her education has laid a strong academic foundation for her research in RF, antennas, and communication systems.

Experience 

Dr. Sapna B A has over two decades of diverse professional experience in academia and industry. She is currently an Assistant Professor at Kalaignarkarunanidhi Institute of Technology, Coimbatore, leading the Ansys 5G Antenna Innovation Hub and successfully completing AICTE-funded projects. Previously, she was a Research Scholar at PSG College of Technology, where she worked extensively on planar and UWB antenna development. Her academic journey also includes faculty positions at INFO Institute of Engineering, RVS College of Engineering, B S A Crescent Engineering College, and CSI College of Engineering. She also served in Dubai as a Design & Estimation Engineer.

Awards and Honors 

Dr. Sapna B A has received several prestigious recognitions for her research and teaching excellence. She was honored with the Best Paper Award for her work on an implantable endoscopic antenna at an IEEE-sponsored international conference. She received the Faculty Excellence Award SNS Institutions for outstanding contributions in research and publication. Her dedication to impactful research has earned her multiple cash awards, Kalaignarkarunanidhi Institute of Technology. Her achievements highlight her commitment to innovation in antenna design and her consistent contributions to advancing communication engineering research.

Research Focus 

Dr. Sapna B A’s research is centered on high-performance antennas for wireless communication, wearable systems, and biomedical applications. She has specialized in designing compact, flexible, and biocompatible implantable antennas with low specific absorption rates to ensure patient safety in medical telemetry. Her work extends to planar and UWB antennas, bandwidth enhancement, gain improvement techniques, and frequency selective surfaces. She has contributed significantly to wearable antenna systems for healthcare monitoring, WBAN applications, and cancer detection. Through experimental validation and simulation studies, her research bridges practical biomedical needs with advanced RF design, positioning her as a leading contributor in antenna engineering.

Publication Top Notes

Gaetan Ligat | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Gaetan Ligat | Drug Discovery and Development | Best Researcher Award

Assoc. Prof. Dr. Gaetan Ligat at Toulouse University | France

Assoc. Prof. Dr. Gaetan Ligat is a molecular virologist and principal investigator at Toulouse University, affiliated with INSERM UMR1291 and CNRS UMR5051. He leads the ViNeDys team at the Toulouse Institute for Infectious and Inflammatory Diseases, focusing on host–human cytomegalovirus interactions in brain tumors and therapeutic innovation. With extensive research and teaching experience across France, he has contributed to advancing antiviral strategies, mentoring young scientists, and promoting scientific communication. He is actively engaged in international collaborations, scientific societies, and community outreach, while securing multiple research grants to strengthen translational virology and oncology research.

Publication Profile 

Google Scholar

Education 

Assoc. Prof. Dr. Gaetan Ligat pursued his scientific training at Limoges University, France. He earned a Master of Science degree in Genetics and Physiology, which laid the foundation for his research career. He then advanced to doctoral studies at INSERM UMR1092, Limoges University, where he specialized in Molecular Virology, completing his PhD with distinction. His academic formation emphasized molecular biology, virus-host interactions, and translational virology, providing expertise in genetics, physiology, and applied biomedical sciences. This strong educational background enabled him to develop a career bridging fundamental research and therapeutic applications, particularly in virology, cancer biology, and innovative antiviral treatment strategies.

Experience 

Assoc. Prof. Dr. Gaetan Ligat is Associate Professor of Virology at Toulouse University, where he also serves as Principal Investigator and group leader of the ViNeDys team at the Infinity Institute. His work focuses on host–HCMV interactions and therapeutic innovation in brain tumors. Previously, he was a postdoctoral researcher at INSERM UMR1110 in Strasbourg, specializing in antiviral strategies. He began his research as a Master’s and PhD candidate at INSERM UMR1092, Limoges. Alongside research, he has coordinated training programs, practical courses, and supervised over 20 students. He is deeply involved in scientific societies, equality initiatives, and international collaborations.

Awards and Honors 

Assoc. Prof. Dr. Gaetan Ligat has received numerous prestigious recognitions, including the National Thesis Prize from the French Society of Microbiology and fellowships from the French National Agency for Research on AIDS and Viral Hepatitis (ANRS). He was awarded an ESCMID Research Grant, travel grants from the French Society of Microbiology, and registration bursaries for international congresses. His successful fundraising as principal investigator includes support from cancer foundations, patient associations, and Inserm/Regional PhD funding. These honors reflect both his scientific excellence and commitment to translational virology and oncology research. His awards highlight his impact on advancing antiviral and therapeutic research.

Research Focus 

Assoc. Prof. Dr. Gaetan Ligat research focuses on the molecular biology of human cytomegalovirus (HCMV) and its interaction with host cells, particularly in brain tumor environments. His work aims to understand how viral mechanisms contribute to disease progression and to identify novel therapeutic targets. He develops innovative antiviral strategies, including peptides and antibodies targeting HCMV protein interactions. His research also explores inflammatory responses, host-pathogen dynamics, and translational approaches for cancer treatment. Through collaborative projects and funded research programs, he seeks to bridge fundamental virology with therapeutic innovation, advancing the fight against viral infections and HCMV-related diseases in oncology.

Publication Top Notes

The human cytomegalovirus terminase complex as an antiviral target: a close-up view

Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives

Hepatitis C virus (HCV)–apolipoprotein interactions and immune evasion and their impact on HCV vaccine design

Hepatitis B virus–host interactions and novel targets for viral cure

Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma

Targeting viral cccDNA for cure of chronic hepatitis B

The Yin and the Yang of extracellular vesicles during viral infections

Structures and divergent mechanisms in capsid maturation and stabilization following genome packaging of human cytomegalovirus and herpesviruses

Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: benefits and limits of 3D analysis

Interferon‐Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection

Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit

Identification of amino acids essential for viral replication in the HCMV helicase-primase complex

Priya Bhosale | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Priya Bhosale | Clinical Trials | Best Researcher Award

Professor of radiology at MD Anderson Cancer Center | United States

Dr. Priya Bhosale is a distinguished Professor of Diagnostic Radiology at The University of Texas MD Anderson Cancer Center, specializing in abdominal and gynecologic imaging. With a career marked by academic excellence, clinical leadership, and pioneering research, she has significantly advanced imaging techniques for cancer diagnosis and treatment planning. She has held numerous leadership roles, contributed to international cancer care guidelines, and mentored emerging medical professionals. Renowned for her dedication to innovation and quality improvement, Dr. Bhosale actively participates in professional societies, editorial boards, and multidisciplinary initiatives, striving to enhance patient care, radiology practice standards, and global collaboration in oncologic imaging.

Publication Profile 

Google Scholar

Education 

Dr. Priya Bhosale earned her MD in Medicine from D.Y. Patil Medical College, Kolhapur, India, followed by advanced radiology training at the University of Pennsylvania and a fellowship at MD Anderson Cancer Center. She has pursued multiple leadership, innovation, and management programs at prestigious institutions including MD Anderson, the American College of Radiology, Association of University Radiologists, and Rice University. Her academic credentials also include an MBA in Health Care Management and Corporate Strategy. These diverse educational experiences have equipped her with expertise in clinical excellence, leadership development, strategic planning, quality control, corporate innovation, and emotional intelligence, all applied to medical practice.

Experience 

Dr. Priya Bhosale has served at MD Anderson Cancer Center progressing from Assistant Professor to Professor in Diagnostic Radiology. She holds concurrent appointments at UT Health Science Center in Houston. She has directed numerous programs including the Quantitative Imaging Core, chaired key quality committees, and led gynecologic imaging initiatives. Beyond academic roles, she has contributed to national and international cancer committees, served as course director, and collaborated in multidisciplinary research. Her leadership spans peer review committees, strategic planning groups, and educational programs, impacting both institutional and global radiology practices through innovation, quality improvement, and patient-centered imaging advancements.

Awards & Honors 

Dr. Priya Bhosale has been recognized through competitive leadership program nominations, including the MD Anderson Leadership Institute and the Radiology Leadership Institute. She has been entrusted with chairing influential national committees such as those in the Society for Advanced Body Imaging and the Texas Radiological Society. Her selection for prestigious executive education at Rice University underscores her leadership stature. She has served as an invited moderator, panelist, and presiding officer at leading radiology and oncology conferences, highlighting her expertise and influence. Through her work, she has advanced imaging research, quality standards, and multidisciplinary collaboration, earning respect across academic, clinical, and research communities.

Research Focus

Dr. Priya Bhosale research centers on advanced abdominal and gynecologic cancer imaging, with an emphasis on MRI applications, quantitative imaging, and multi-modality diagnostic strategies. She develops and evaluates imaging biomarkers to improve cancer detection, staging, treatment planning, and response assessment. Her work integrates radiology with pathology and oncology to refine precision medicine approaches. She also investigates quality improvement in imaging protocols and reproducibility in multi-center trials. As an active member of national cancer steering committees and working groups, she contributes to shaping imaging guidelines, fostering innovation, and translating research into practice to enhance outcomes for patients with complex oncologic diseases.

Publication Top Notes

Frequent detection of pancreatic lesions in asymptomatic high-risk individuals

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head

Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis

Ovarian cancer, the revised FIGO staging system, and the role of imaging

Predictors and patterns of recurrence after definitive chemoradiation for anal cancer

The inguinal canal: anatomy and imaging features of common and uncommon masses

Transport properties of pancreatic cancer describe gemcitabine delivery and response

Imaging of pancreatic adenocarcinoma: update on staging/resectability

Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience

Cervical cancer: 2018 revised international federation of gynecology and obstetrics staging system and the role of imaging

Imaging and staging of endometrial cancer

Chemotherapy induced liver abnormalities: an imaging perspective

Imaging features of carcinoid tumors of the gastrointestinal tract

Aiyin Chen | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Aiyin Chen | Clinical Trials | Best Researcher Award

Associate Professor at Oregon Health & Science University | United States

Dr. Aiyin Chen is an accomplished ophthalmologist and glaucoma specialist, recognized for her expertise in clinical care, research, and academic leadership. She serves as an Associate Professor in the Department of Ophthalmology at Oregon Health & Science University’s Casey Eye Institute. Dr. Chen’s career bridges advanced patient care with groundbreaking research in glaucoma detection, machine learning risk prediction, and optical coherence tomography applications. She has led and collaborated on multiple NIH-funded projects, contributed extensively to peer-reviewed literature, and worked to improve vision health in underserved populations. Dedicated to advancing ophthalmic science, Dr. Chen’s work continues to shape the future of glaucoma care.

Publication Profile 

Google Scholar

Education 

Dr. Aiyin Chen earned her Bachelor of Arts degree in Biological Sciences with a Neurobiology and Behavior concentration from Cornell University, graduating magna cum laude with distinction. She obtained her Doctor of Medicine with thesis distinction from the University of California, San Francisco (UCSF) School of Medicine. Following medical school, she completed a transitional internship at Atlantic Health Morristown Memorial Hospital and Mount Sinai School of Medicine. Dr. Chen then pursued ophthalmology residency training and a glaucoma fellowship at UCSF. She is certified by the American Board of Ophthalmology and holds active medical licenses in Oregon, Washington, and California, with prior licensure in Nevada.

Experience 

Dr. Aiyin Chen professional journey includes service as a glaucoma specialist at Wellish Vision Institute, and surgical roles at Sunrise Hospital and Box Canyon Surgery Center in Las Vegas. She transitioned to academia at the Casey Eye Institute, Oregon Health & Science University, where she served as Assistant Professor before advancing to Associate Professor. Her clinical expertise encompasses complex glaucoma management and surgery, while her administrative and teaching roles support training the next generation of ophthalmologists. Dr. Chen has been deeply involved in multi-institutional research collaborations, NIH-funded studies, and projects integrating telemedicine and big data analytics to improve glaucoma detection, diagnosis, and patient outcomes.

Awards and Honors 

Dr. Aiyin Chen has earned multiple distinctions throughout her academic and professional career, including thesis distinction during her MD program and recognition for her NIH-funded research contributions in ophthalmology. She has been selected as a K12 Clinical Scientist Institutional Career Development Awardee, underscoring her leadership in translational research. Her grant portfolio includes principal investigator and co-investigator roles on high-impact glaucoma studies funded by the National Eye Institute and National Library of Medicine. Dr. Chen’s scholarship, mentorship, and commitment to improving vision health in underserved communities have established her as a leader in ophthalmic research, earning her recognition among peers in the global vision science community.

Research Focus 

Dr. Aiyin Chen research focuses on advancing glaucoma detection, risk prediction, and disease management through technology-driven approaches. Her work includes developing machine learning models to predict glaucoma onset and progression, exploring the use of optical coherence tomography angiography for early diagnosis, and designing telemedicine-based screening strategies for underserved areas. She has contributed to studies evaluating clinic efficiency through data modeling and examined ocular blood flow in glaucoma patients before and after surgical interventions. With a strong record of NIH-funded research, Dr. Chen’s efforts aim to integrate imaging, big data analytics, and community outreach to improve glaucoma care worldwide.

Publication Top Notes

Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Measuring glaucomatous focal perfusion loss in the peripapillary retina using OCT angiography

Semaglutide and nonarteritic anterior ischemic optic neuropathy

Scleral intraocular pressure measurement in cadaver eyes pre-and postkeratoprosthesis implantation

Patterns of neural activation associated with exposure to odors from a familiar winner in male golden hamsters

Asian herbal-tobacco cigarettes:“not medicine but less harmful”?

Effect of algorithms and covariates in glaucoma diagnosis with optical coherence tomography angiography

Focal loss analysis of nerve fiber layer reflectance for glaucoma diagnosis

Prediction of multiclass surgical outcomes in glaucoma using multimodal deep learning based on free-text operative notes and structured EHR data

Extraction of active medications and adherence using natural language processing for glaucoma patients

Integrating deep learning with electronic health records for early glaucoma detection: a multi-dimensional machine learning approach

Emerging frontline leaders’ voices in response to COVID-19 crisis

Surgical management of an optic nerve glioma with perineural arachnoidal gliomatosis growth pattern

Optical coherence tomographic angiography detects retinal vascular changes associated with pituitary adenoma

Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award

Licenced Physician with a doctoral degree (MD) at Department of Medicine V, University Hospital, LMU Munich | Germany

Dr. med. Laura Lambrecht, born in Munich, is a dedicated physician specializing in pneumology and cardiology with a strong research background in experimental adult cardiology. She completed her medical studies at Ludwig-Maximilians-Universität München and the Technical University of Munich, earning her approbation as a physician. Her doctoral research at the Deutsches Herzzentrum München focused on the functional impact of acetylsalicylic acid on platelet function in carriers of genetic variants in the GUCY1A1 gene, associated with coronary heart disease risk. She actively contributes to clinical work, academic research, and professional leadership roles, while also engaging in cultural and educational initiatives.

Publication Profile 

Orcid

Education 

Dr. Laura Lambrecht earned her Allgemeine Hochschulreife from Max-Bon-Gymnasium Germering with top marks. She began her pre-clinical medical studies at Ludwig-Maximilians-Universität München, achieving “gut” in her first medical examination. She continued her clinical medical studies at the Technical University of Munich, also earning “gut,” and successfully passed her second and third medical examinations. She obtained her approbation as a physician in December. Her doctoral work at the Deutsches Herzzentrum München investigated the effects of acetylsalicylic acid on platelet function in genetically predisposed individuals. She holds certifications in Good Clinical Practice (GCP) and is a member of the Young-DZHK research network.

Experience 

Dr. Lambrecht is currently a physician in training for pneumology at the LMU Klinikum, with a prior rotation in cardiology at the same institution. She has also served as a cardiology trainee at the Medizinisches Versorgungszentrum Dachau, a teaching practice of LMU Munich. Her research experience includes experimental adult cardiology at the Deutsches Herzzentrum München in the group of Prof. Dr. H. Schunkert. She has held leadership roles such as assistant representative at the LMU Klinikum. Alongside her clinical career, she has been actively involved in student representation, faculty governance, and medical community engagement through various institutional committees and organizations.

Awards and Honors 

Dr. Lambrecht’s academic achievements include graduating from Max-Bon-Gymnasium Germering with “sehr gut” and consistently strong performance in her medical studies at LMU and TU Munich. She earned her approbation as a physician and secured a place in the prestigious Young-DZHK network, reflecting her recognized potential in cardiovascular research. She received funding for her doctoral project examining the genetic and pharmacological interplay in coronary heart disease. Her leadership as assistant representative and elected student council member also reflects peer recognition. Her commitment to academic excellence, research innovation, and community service positions her as a promising contributor to both clinical and research fields.

Research Focus 

Dr. Lambrecht’s primary research interest lies in cardiovascular pharmacogenetics, particularly the influence of genetic variants on drug response. Her doctoral project focused on the functional effects of acetylsalicylic acid on platelet function in carriers of genetic variants in the coronary heart disease risk gene GUCY1A1. She is interested in translating molecular findings into personalized therapeutic strategies for cardiovascular patients. Her work integrates clinical cardiology with laboratory-based functional assays to better understand genotype-specific treatment responses. Additionally, she engages in interdisciplinary collaboration between cardiology and pneumology, aiming to address comorbid conditions and improve patient care through evidence-based, precision medicine approaches.

Publication Top Notes

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.

Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation.